T2 Biosystems Presents Data on the Company’s T2MR® Technology for the Detection of the Bacteria that Causes Lyme Disease Directly from Whole Blood at Cold Spring Harbor Laboratory Conference on Diagnostic Tests for Lyme Disease

LEXINGTON, Mass., Sept. 21, 2016 -- T2 Biosystems, Inc. (NASDAQ:TTOO), a company developing innovative diagnostic products to improve patient health, announced that Tom Lowery, Ph.D., chief scientific officer, today presented data on the T2 Magnetic Resonance (T2MR^®) technology for the detection of Borrelia – the bacteria that causes Lyme disease – directly from whole blood samples. The data were presented at the Diagnostic Tests for Lyme Disease Conference at the Banbury Center at Cold Spring Harbor Laboratory in New York.

Dr. Lowery’s Lyme disease presentation included limit of detection data of <10 cells/mL and data demonstrating T2MR detection of Borrelia in samples from patients in early stages of the disease. In addition, Dr. Lowery presented results from previously reported studies of the Company’s T2Candida^® and T2Bacteria™ Panels, including limit of detection data for the T2Bacteria Panel of <5 CFU/mL.

“According to the CDC, roughly 30,000 cases of Lyme disease are reported in the U.S. each year; yet, the current diagnostic testing market remains poor. Patients are frequently misdiagnosed or face delayed diagnosis, and there are almost 300,000 patients that are undiagnosed, despite over 3 million tests run annually in the U.S. alone,” said John McDonough, president and CEO of T2 Biosystems. “The data presented at Cold Spring Harbor Laboratory illustrate the early success of our T2MR technology in this area of important unmet medical need, including its ability to rapidly detect Borrelia without the need for blood culture. A timely diagnosis of Lyme disease may help prevent the evolution of the disease to its later stages, and ultimately, eliminate the significant costs associated with these effects. We look forward to further developing this technology and eventually introducing the T2Lyme™ Panel, a test we’re developing in partnership with our partner, Canon U.S. Life Sciences.”

About T2 Biosystems
T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, eliminating the time-consuming sample prep required in current methods. The T2Candida Panel was cleared for marketing by the U.S. Food and Drug Administration (FDA) in September 2014 for the detection of sepsis-causing Candida. T2Candida Panel performance was established in adult subjects. T2Candida Panel performance in neonates, infants, and pediatric patients has not been established. For more information, please visit www.t2biosystems.com.

Media Contact:
Susan Heins, Pure Communications
[email protected]
864.286.9597

Investor Contact:
Matt Clawson, Pure Communications
[email protected]
949-370-8500